SAI Life Sciences Ltd.NSE: SAILIFE

Press Release Jan 28 2026

· Issued by SAI Life Sciences Ltd.

Filed with NSE · · 3 pages · English

Summary by 6ix AI

SAI Life Sciences Ltd. has announced a strategic collaboration with Mabtech to enhance immunology research at its Boston site, establishing it as a co-marketed hub for the Mabtech EYRA platform. This partnership aims to provide advanced immunology assay services, including multiplex cytokine workflows, to biopharma and biotech companies. The collaboration is designed to accelerate access to next-generation immune profiling capabilities in various therapeutic areas such as immuno-oncology and vaccines.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Sai Life Sciences Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Strategic Collaboration Between Mabtech and Sai Life Sciences to Advance Immunology Research with EYRA Platform at Sai Boston Site.

SAI Life Sciences Ltd. on 6ix

Earlier from SAI Life Sciences

Later from SAI Life Sciences

All SAI Life Sciences news releases